Search clinical trials for: Gleevec intolerant

Total 1642 results

M.D. Anderson Cancer Center

Completed

Gleevec Study for Patients With Ovarian Cancer

Ovarian Cancer

United States
HK inno.N Corporation

Completed

to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers

Healthy

Korea, Republic of
University Hospital, Motol

Unknown

Prediction of Carotid Occlusion Intolerance by Transcranial Doppler Evaluation in Patients Undergoing Carotid Artery Stenting With Proximal Flow Arrest Protection System.

Carotid Occlusion Intolerance

Czech Republic
West Virginia School of Osteopathic Medicine

Completed

Biomarkers of Metabolic Syndrome and Prediabetes

Hypertension | Diabetes | Metabolic Syndrome | Prediabetes

United States
Yale University

Completed

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Obesity | Type 2 Diabetes Mellitus | Impaired Glucose Tolerance

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

Gastrointestinal Stromal Tumor

United States
Pfizer

Terminated

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

Metastatic Renal Cell Carcinoma

Philippines
Charles Drew University of Medicine and Science
American Diabetes Association

Completed

Vitamin D in Minorities With Prediabetes

Pre-diabetes

United States
Tethys Bioscience, Inc.

Unknown

Prospective Observational Study Assessing Treatment and Outcomes of Patients With Prediabetes

Prediabetes
National Cancer Institute (NCI)

Terminated

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Unity Health Toronto

Unknown

Effect of Ginseng on Glycemic Control

Diabetes | Impaired Glucose Tolerance

Canada
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

Cardiovascular Disease | Insulin Resistance | Pediatric Obesity | Impaired Glucose Tolerance

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Myelogenous Leukemia, Chronic

China
Johns Hopkins University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study) (SHAPE3)

Obesity | Overweight | Type 2 Diabetes | Prediabetes

United States
Takeda

Completed

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

United States, Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, South Africa, Ukraine
Chelsea Therapeutics

Completed

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Symptomatic Neurogenic Orthostatic Hypotension

United States
Duke University
Novartis Pharmaceuticals

Completed

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Glioblastoma | Gliosarcoma

United States
TSH Biopharm Corporation Limited

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients (OH)

Orthostatic Hypotension

Taiwan
University of Padova

Completed

Metformin and Longevity Genes in Prediabetes

Inflammation | Insulin Resistance | Aging | Prediabetes

Italy
University of Roma La Sapienza

Unknown

Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients (CHOLESS)

Coronary Artery Disease

Italy
University of Roma La Sapienza

Unknown

Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients (ECLIPSE)

Coronary Artery Disease

Italy
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Fibrosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Gastrointestinal Stromal Tumor

United States
Annick Desjardins
Novartis Pharmaceuticals

Completed

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Glioblastoma | Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Abbott Nutrition

Completed

Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula

Infant | Gastrointestinal Intolerance

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States
Peking University Cancer Hospital & Institute

Unknown

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Melanoma

China
SCRI Development Innovations, LLC
Novartis; Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
National Cancer Institute (NCI)

Completed

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Duke University
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Glioblastoma | Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Testicular Seminoma | Recurrent Ovarian Germ Cell Tumor | Stage II Ovarian Germ Cell Tumor | Stage III Ovarian Germ Cell Tumor | Ovarian Dysgerminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Unspecified Adult Solid Tumor, Protocol Specific | Malignant Neoplasm

United States
Tel-Aviv Sourasky Medical Center

Unknown

The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Postural Tachycardia Syndrome
Yale University
Amylin Pharmaceuticals, LLC.

Withdrawn

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

Obesity | Cardiovascular Disease | Insulin Resistance | Impaired Glucose Tolerance
Annick Desjardins
AstraZeneca; Novartis Pharmaceuticals

Completed

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Glioblastoma | Gliosarcoma

United States
VeraLight, Inc.

Completed

Evaluation of Low Source of Signal in SCOUT DS (LSS)

Metabolic Syndrome | Impaired Glucose Tolerance | Gestational Diabetes

United States
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System

Completed

Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)

Prediabetes | Impaired Fasting Glucose
NYU Langone Health
Novartis

Terminated

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Ovarian Cancer

United States
Nestlé

Completed

Althera® Versus Nutramigen / Cow's Milk Intolerance

Allergy

Belgium
Fundación Cardiovascular de Colombia
AstraZeneca

Terminated

Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects (ARAMIA)

Obesity | Glucose Intolerance

Colombia

Search clinical trials for: Gleevec intolerant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations